<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>同写意 | wechat-feeds</title><link>http://MzA4MzgzMDM5Mg.favicon.privacyhide.com/favicon.ico</link><description>一个以新药创制为核心，汇集国内一流研发精英的大型交流与价值分享平台。“同筑技术人生路，写意中国新药魂”是同写意的初衷与愿景。秉承汇集“一线、一流”，讲求“实用、实在、时效”的原则。</description><managingEditor> (hellodword)</managingEditor><pubDate>Thu, 08 Apr 2021 23:24:12 +0800</pubDate><image><url>http://MzA4MzgzMDM5Mg.favicon.privacyhide.com/favicon.ico</url><title>同写意 | wechat-feeds</title><link>http://MzA4MzgzMDM5Mg.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>写意讨论丨ADC药物的创新发展之路</title><link>https://mp.weixin.qq.com/s/ysWkPdKFfwV7XBvJKAIhKg</link><description></description><content:encoded><![CDATA[写意讨论丨ADC药物的创新发展之路]]></content:encoded><pubDate>Thu, 08 Apr 2021 21:40:08 +0800</pubDate></item><item><title>晶泰科技携手希格生科，推动弥漫性胃癌项目获重大进展</title><link>https://mp.weixin.qq.com/s/vTfL064hzsSYYTHWhCpN7g</link><description></description><content:encoded><![CDATA[晶泰科技携手希格生科，推动弥漫性胃癌项目获重大进展]]></content:encoded><pubDate>Thu, 08 Apr 2021 21:40:08 +0800</pubDate></item><item><title>当Me-too变成We-too，中国创新药之路该怎么走？</title><link>https://mp.weixin.qq.com/s/hKcuGkHTFHwy0hG1daqRmg</link><description></description><content:encoded><![CDATA[当Me-too变成We-too，中国创新药之路该怎么走？]]></content:encoded><pubDate>Thu, 08 Apr 2021 21:40:08 +0800</pubDate></item><item><title>审批屡遭延迟/拒绝，FDA监管政策在收紧？</title><link>https://mp.weixin.qq.com/s/vSEHzhKpZJigrm3mDeEIeA</link><description></description><content:encoded><![CDATA[审批屡遭延迟/拒绝，FDA监管政策在收紧？]]></content:encoded><pubDate>Thu, 08 Apr 2021 21:40:08 +0800</pubDate></item><item><title>艾博生物宣布完成6亿元B轮融资，加速新冠疫苗研发、建设疫苗产业基地并进一步扩充产品管线</title><link>https://mp.weixin.qq.com/s/qqQ8PwIZB-EX-qVEjBIASg</link><description></description><content:encoded><![CDATA[艾博生物宣布完成6亿元B轮融资，加速新冠疫苗研发、建设疫苗产业基地并进一步扩充产品管线]]></content:encoded><pubDate>Wed, 07 Apr 2021 18:55:23 +0800</pubDate></item><item><title>带你认识溶瘤病毒，从外行到行家</title><link>https://mp.weixin.qq.com/s/bAm3Bm81UyW5xG3DJ_Iuhg</link><description></description><content:encoded><![CDATA[带你认识溶瘤病毒，从外行到行家]]></content:encoded><pubDate>Wed, 07 Apr 2021 18:55:23 +0800</pubDate></item><item><title>植德写意丨药物警戒：药物全生命周期的风险监管制度（下）</title><link>https://mp.weixin.qq.com/s/ebafRt0UYLf0KA6GAWhfWQ</link><description></description><content:encoded><![CDATA[植德写意丨药物警戒：药物全生命周期的风险监管制度（下）]]></content:encoded><pubDate>Wed, 07 Apr 2021 18:55:23 +0800</pubDate></item><item><title>药物命名中的玄机—FDA发布药物命名新指南</title><link>https://mp.weixin.qq.com/s/KRU4FG8RLTwAmEqUDMso3A</link><description></description><content:encoded><![CDATA[药物命名中的玄机—FDA发布药物命名新指南]]></content:encoded><pubDate>Wed, 07 Apr 2021 18:55:23 +0800</pubDate></item><item><title>活动推荐丨PCPI论坛：临床大咖齐聚苏州，共创新药研发良好生态！</title><link>https://mp.weixin.qq.com/s/AuCOJMrzNVw9jmVNUo1Tzw</link><description></description><content:encoded><![CDATA[活动推荐丨PCPI论坛：临床大咖齐聚苏州，共创新药研发良好生态！]]></content:encoded><pubDate>Wed, 07 Apr 2021 18:55:23 +0800</pubDate></item><item><title>同写意承办丨首届河套国际医药论坛</title><link>https://mp.weixin.qq.com/s/jzBQ1ZeCsJWdT5Z0rk_5Ow</link><description></description><content:encoded><![CDATA[同写意承办丨首届河套国际医药论坛]]></content:encoded><pubDate>Tue, 06 Apr 2021 21:46:31 +0800</pubDate></item><item><title>关注杜丨十年来首款，又一多动症治疗新药获FDA批准</title><link>https://mp.weixin.qq.com/s/K1LJlx-FLdqm0e2U8rEEJA</link><description></description><content:encoded><![CDATA[关注杜丨十年来首款，又一多动症治疗新药获FDA批准]]></content:encoded><pubDate>Tue, 06 Apr 2021 21:46:31 +0800</pubDate></item><item><title>PROTAC的昨天、今天和明天</title><link>https://mp.weixin.qq.com/s/1PAlG4w5eGpnhX574w4nhw</link><description></description><content:encoded><![CDATA[PROTAC的昨天、今天和明天]]></content:encoded><pubDate>Tue, 06 Apr 2021 21:46:31 +0800</pubDate></item><item><title>同写意丨药明直播间：肿瘤免疫系列(八)—RAS通路肿瘤治疗药物的研发</title><link>https://mp.weixin.qq.com/s/5gw2_xX1Vl8DuES7hzqrlw</link><description></description><content:encoded><![CDATA[同写意丨药明直播间：肿瘤免疫系列(八)—RAS通路肿瘤治疗药物的研发]]></content:encoded><pubDate>Tue, 06 Apr 2021 21:46:31 +0800</pubDate></item><item><title>小分子PD-L1抑制剂：再极医药、红日药业、微芯生物、歌礼制药、东阳光、南京圣和</title><link>https://mp.weixin.qq.com/s/u7zB6dYCfK7bJoMyl-YFEg</link><description></description><content:encoded><![CDATA[小分子PD-L1抑制剂：再极医药、红日药业、微芯生物、歌礼制药、东阳光、南京圣和]]></content:encoded><pubDate>Mon, 05 Apr 2021 21:31:59 +0800</pubDate></item><item><title>泰诺麦博数字化抗体生产基地竣工暨投产仪式隆重举行！</title><link>https://mp.weixin.qq.com/s/OvBCFERQK0lzvkZqvFxYKA</link><description></description><content:encoded><![CDATA[泰诺麦博数字化抗体生产基地竣工暨投产仪式隆重举行！]]></content:encoded><pubDate>Mon, 05 Apr 2021 21:31:59 +0800</pubDate></item><item><title>又一家上市药企涉嫌原料药垄断被罚！</title><link>https://mp.weixin.qq.com/s/hPNHoaQE20glf04dhXZkCA</link><description></description><content:encoded><![CDATA[又一家上市药企涉嫌原料药垄断被罚！]]></content:encoded><pubDate>Mon, 05 Apr 2021 21:31:59 +0800</pubDate></item><item><title>齐鲁制药3500万license in，新一代ADC获新进展</title><link>https://mp.weixin.qq.com/s/6u4AQGyHJicwbS1fLV0XrA</link><description></description><content:encoded><![CDATA[齐鲁制药3500万license in，新一代ADC获新进展]]></content:encoded><pubDate>Sun, 04 Apr 2021 21:37:24 +0800</pubDate></item><item><title>FDA加速批准——新药研发与审评的加速通道</title><link>https://mp.weixin.qq.com/s/9if7tbg1IJyK4H6YOv5shg</link><description></description><content:encoded><![CDATA[FDA加速批准——新药研发与审评的加速通道]]></content:encoded><pubDate>Sun, 04 Apr 2021 21:37:24 +0800</pubDate></item><item><title>写意发布丨同写意制药工程俱乐部成立</title><link>https://mp.weixin.qq.com/s/aL33HKLAcDBMQL7c8wmxkg</link><description></description><content:encoded><![CDATA[写意发布丨同写意制药工程俱乐部成立]]></content:encoded><pubDate>Sat, 03 Apr 2021 18:49:33 +0800</pubDate></item><item><title>同写意第117期丨2021独墅湖国际药品质量研究论坛</title><link>https://mp.weixin.qq.com/s/xpJfaS4VJis_OyHw2oCZdQ</link><description></description><content:encoded><![CDATA[同写意第117期丨2021独墅湖国际药品质量研究论坛]]></content:encoded><pubDate>Sat, 03 Apr 2021 18:49:33 +0800</pubDate></item></channel></rss>